Reviva Pharmaceuticals Provides Update on Clinical Development Pipeline

Jul 27, 2022 | Press Releases

Enrollment remains on pace for Reviva’s Phase 3 clinical trial for the treatment of schizophrenia at 15 sites across the US with enrollment set to begin at sites in Europe and India in Q3 2022 More than 20% of the approximately 400 patients planned for Phase 3...

Reviva Pharmaceuticals to Participate in the 2022 BIO International Convention

Jun 2, 2022 | Press Releases

CUPERTINO, Calif.,, June 02, 2022 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...

Reviva Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

May 17, 2022 | Press Releases

CUPERTINO, Calif., May 17, 2022 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...

Reviva Pharmaceuticals Holdings, Inc. Reports First Quarter 2022 Financial Results and Recent Business Highlights

May 16, 2022 | Press Releases

– Hosted key opinion leader (KOL) webinar on brilaroxazine for schizophrenia and other neuropsychiatric disorders led by industry thought leaders Leslie Citrome, MD & Larry Ereshefsky, PharmD – Topline data for pivotal Phase 3 trial evaluating...

Reviva Pharmaceuticals Announces Update on RECOVER, a Pivotal Phase 3 Global Study Evaluating Brilaroxazine for the Treatment of Schizophrenia

May 3, 2022 | Press Releases

CUPERTINO, Calif., May 03, 2022 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...